Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan-Fang Xing

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Medicine|June 29, 2017
A multidisciplinary team approach for nutritional interventions conducted by specialist nurses in patients with advanced colorectal cancer undergoing chemotherapy: A clinical trialJin-Xiang Lin, Xiang-Wei Chen, Zhan-Hong Chen, et al.
Oncotarget|May 18, 2017
Advance directives: cancer patients' preferences and family-based decision makingYan-Fang Xing, Jin-Xiang Lin, Xing Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 24, 2020
Expansion of Group 2 Innate Lymphoid Cells in Patients with End-Stage Renal Disease and Their Clinical SignificanceGao-Yu Liu, Xiao-Hui Deng, Xing Li, et al.
Liver Research (Beijing, China)|January 28, 2026
Cancer cachexia-related monocytic myeloid-derived suppressor cells impair T-cell negative selection and predict immune-related adverse eventsLi Wei, Ya-Qin Sun, Jian-Hua Ren, et al.
Asia-Pacific Journal of Clinical Oncology|January 3, 2013
Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trialsXing Li, Min Dong, Qu Lin, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 16, 2025
Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and ToxicityRun-Kai Huang, Yan-Fang Xing, Xiang-Yuan Wu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 21, 2014
Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinomaXing Li, Zhan-Hong Chen, Yan-Fang Xing, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 28, 2012
An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot studyXiang-Yuan Wu, Xing Li, Zhan-Hong Chen, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|January 9, 2016
Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial ChemoembolizationXing Li, Xiang Zhong, Zhan-Hong Chen, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|December 19, 2014
Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patientsXing Li, Xiang Zhong, Zhan-Hong Chen, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Medicine|June 29, 2017
A multidisciplinary team approach for nutritional interventions conducted by specialist nurses in patients with advanced colorectal cancer undergoing chemotherapy: A clinical trialJin-Xiang Lin, Xiang-Wei Chen, Zhan-Hong Chen, et al.
Oncotarget|May 18, 2017
Advance directives: cancer patients' preferences and family-based decision makingYan-Fang Xing, Jin-Xiang Lin, Xing Li, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 24, 2020
Expansion of Group 2 Innate Lymphoid Cells in Patients with End-Stage Renal Disease and Their Clinical SignificanceGao-Yu Liu, Xiao-Hui Deng, Xing Li, et al.
Liver Research (Beijing, China)|January 28, 2026
Cancer cachexia-related monocytic myeloid-derived suppressor cells impair T-cell negative selection and predict immune-related adverse eventsLi Wei, Ya-Qin Sun, Jian-Hua Ren, et al.
Asia-Pacific Journal of Clinical Oncology|January 3, 2013
Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trialsXing Li, Min Dong, Qu Lin, et al.
Journal of Cachexia, Sarcopenia and Muscle|July 16, 2025
Thymic Microenvironment Remodeling in Cancer Cachexia as a Determinant of Checkpoint Inhibitor Efficacy and ToxicityRun-Kai Huang, Yan-Fang Xing, Xiang-Yuan Wu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 21, 2014
Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinomaXing Li, Zhan-Hong Chen, Yan-Fang Xing, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 28, 2012
An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot studyXiang-Yuan Wu, Xing Li, Zhan-Hong Chen, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|January 9, 2016
Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial ChemoembolizationXing Li, Xiang Zhong, Zhan-Hong Chen, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|December 19, 2014
Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patientsXing Li, Xiang Zhong, Zhan-Hong Chen, et al.
Pageof 3